Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Health Canada recall

This article was originally published in The Tan Sheet

Executive Summary

Health Canada announces July 27 consumers should not use unauthorized smoking cessation product Resolve because of potential health risks. The product contains Cestemenol-350, which may result in damage to the kidney, liver or red blood cells, according to Health Canada. Resolve, distributed by The Winning Combination, is advertised as a natural stop-smoking aid comes in cool peppermint and wild cherry flavors. FDA says it is unaware of any marketing of the product in the U.S. except through onlinemarketing or from Canadian sources. Health Canada said it was is recalling the product immediately...

You may also be interested in...

Winning Combination loses NAD challenge

The Winning Combination should discontinue claims that its Resolve smoking cessation aid is "clinically proven" to help smokers quit "once and for all" with "less stress and anxiety," the National Advertising Division says Oct. 28. NAD advises the advertiser to discontinue broad efficacy claims and some testimonials. The Winnipeg, Manitoba-based firm claims Resolve has natural ingredients and that the key ingredient ethyl maltol reduces cigarette consumption. The Winning Combination disagrees with NAD, but "will accede to the requests." GlaxoSmithKline, which sells Nicorette, Commit and NicoDerm CQ OTC NRT products, brought the challenge. In August 2008, Health Canada stated Resolve remains unauthorized for use there following a June 2007 advisory and recall the agency issued concerning the ingredient Cestemenol-350. The agency said in excessive amounts, Cestemenol-350 may cause damage to the kidney, liver or red blood cells (1"The Tan Sheet" Aug. 6, 2007, In Brief)

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California

US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts